Trinity Biotech (TRIB) Capital Leases (2016 - 2025)

Trinity Biotech (TRIB) has reported Capital Leases for 10 consecutive years, with $10.8 million the latest figure, recorded in Q4 2025.

• Quarterly Capital Leases rose 3.46% year-over-year to $10.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.8 million (up 3.46% YoY) and the FY2025 annual result came in at $10.8 million, up 3.46% from the prior year.
• Capital Leases advanced to $10.8 million in Q4 2025 per TRIB's latest filing, from $10.5 million in the prior quarter.
• Over the last five years, Capital Leases for TRIB reached as high as $13.9 million in Q4 2021 and fell as low as $10.5 million in Q4 2024.
• A 5-year average of $11.7 million and a median of $10.9 million in 2023 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2021 — Capital Leases fell 16.42% — and 2025, when it gained 3.46%.
• Year by year, Capital Leases stood at $13.9 million in 2021, then retreated by 11.53% to $12.3 million in 2022, then retreated by 11.37% to $10.9 million in 2023, then declined by 3.63% to $10.5 million in 2024, then rose by 3.46% to $10.8 million in 2025.
• According to Business Quant data, Capital Leases over the past three periods registered $10.8 million, $10.5 million, and $10.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.